Investigate the clinical subtypes and the biological markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD.
In this proposal, the investigators aim to explore the clinical subtypes and biological markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD. By stratifying the subjects with (versus without) remission and treatment response, the biological markers are expected to have important prediction effects in future clinical practice.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
400
12-week double-blind, randomized controlled trial
China Medical University Hospital
Taichung, Taiwan
Hamilton Rating Scale for Depression (HAMD) Changes
The Changes of scores in Hamilton Rating Scale for Depression
Time frame: From Week 0 to Week 12
Response rate
50% decreases in the Hamilton Rating Scale for Depression from W0 to W12
Time frame: at Week 12
Remission rate
Less than 8 points in the Hamilton Rating Scale for Depression at W12
Time frame: at Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.